Chemical Compound Review:
SureCN331331 4-amino-1-[3,4-dihydroxy-5...
Synonyms:
NSC-63878, NSC-143922, NSC-526786, NSC63878, CTK9A2616, ...
This record was replaced with 596.
- Letter: Ara-C and disseminated zoster. Hines, J.D., Cowan, D.H., Nankervis, G.A. N. Engl. J. Med. (1975)
- Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea. Veith, R., Galanello, R., Papayannopoulou, T., Stamatoyannopoulos, G. N. Engl. J. Med. (1985)
- Visceral herpesvirus infections in leukemic patients receiving cytarabine. Buss, D.H., Scharyj, M., White, D.R. JAMA (1980)
- Transcriptional regulation of c-jun gene expression by arabinofuranosylcytosine in human myeloid leukemia cells. Kharbanda, S.M., Sherman, M.L., Kufe, D.W. J. Clin. Invest. (1990)
- Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response. Burke, P.J., Karp, J.E., Vaughan, W.P. J. Natl. Cancer Inst. (1981)
- Successful pregnancy after allogeneic bone marrow transplantation following conditioning with total body irradiation. Maruta, A., Matsuzaki, M., Miyashita, H., Kodama, F., Kato, H., Taguchi, J., Tomita, N., Sakai, R., Fujisawa, S., Okubo, T. Bone Marrow Transplant. (1995)
- Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia. Tsuruo, T., Oh-Hara, T., Sudo, Y., Naito, M. Anticancer Res. (1993)
- Dose- and stage-related sex difference in the incidence of cytosine arabinoside induced digit anomalies in the mouse fetus. Goto, T., Endo, A. Teratology (1987)
- Conversion disorder with convulsion and motor deficit mimicking the adverse effects of high-dose Ara-C treatment in a posttransplant acute myeloid leukemia patient: a case report and review of the literature. Onishi, H., Kamijo, A., Onose, M., Yamada, T., Mizuno, Y., Ito, M., Saito, H., Maruta, I. Palliative & supportive care. (2004)
- Mechanism of Hb F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C, or hydroxyurea. Galanello, R., Stamatoyannopoulos, G., Papayannopoulou, T. J. Clin. Invest. (1988)
- Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat. McCullough, H.N., Juliano, R.L. J. Natl. Cancer Inst. (1979)
- Effects of cytosine arabinoside on differential gene expression in embryonic neural retina. II. Immunochemical studies on the accumulation of glutamine synthetase. Jones, R.E., Moscona, A.A. J. Cell Biol. (1977)
- Differential protection of normal and malignant human myeloid progenitors (CFU-GM) from Ara-C toxicity using cycloheximide. Slapak, C.A., Fine, R.L., Richman, C.M. Blood (1985)
- Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. Ho, A.D., Haas, R., Wulf, G., Knauf, W., Ehrhardt, R., Heilig, B., Körbling, M., Schulz, G., Hunstein, W. Blood (1990)
- Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. Solary, E., Caillot, D., Chauffert, B., Casasnovas, R.O., Dumas, M., Maynadie, M., Guy, H. J. Clin. Oncol. (1992)
- A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. Hitchins, R.N., Bell, D.R., Woods, R.L., Levi, J.A. J. Clin. Oncol. (1987)
- Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. Weller, M., Müller, B., Koch, R., Bamberg, M., Krauseneck, P. J. Clin. Oncol. (2003)
- Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Datta, R., Banach, D., Kojima, H., Talanian, R.V., Alnemri, E.S., Wong, W.W., Kufe, D.W. Blood (1996)
- Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Roy, L., Guilhot, J., Krahnke, T., Guerci-Bresler, A., Druker, B.J., Larson, R.A., O'Brien, S., So, C., Massimini, G., Guilhot, F. Blood (2006)
- Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Coleman, C.N., Stoller, R.G., Drake, J.C., Chabner, B.A. Blood (1975)
- Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) enhances high-dose Ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells. Bhalla, K., Tang, C., Ibrado, A.M., Grant, S., Tourkina, E., Holladay, C., Hughes, M., Mahoney, M.E., Huang, Y. Blood (1992)
- Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Kim, S., Khatibi, S., Howell, S.B., McCully, C., Balis, F.M., Poplack, D.G. Cancer Res. (1993)
- Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Bhalla, K., Holladay, C., Arlin, Z., Grant, S., Ibrado, A.M., Jasiok, M. Blood (1991)
- Temporal and spatial distribution of DNA topoisomerase II alters during proliferation, differentiation, and apoptosis in HL-60 cells. Sugimoto, K., Yamada, K., Egashira, M., Yazaki, Y., Hirai, H., Kikuchi, A., Oshimi, K. Blood (1998)
- CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Fang, G., Kim, C.N., Perkins, C.L., Ramadevi, N., Winton, E., Wittmann, S., Bhalla, K.N. Blood (2000)
- Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Berman, E., Heller, G., Santorsa, J., McKenzie, S., Gee, T., Kempin, S., Gulati, S., Andreeff, M., Kolitz, J., Gabrilove, J. Blood (1991)
- Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Mudry, R.E., Fortney, J.E., York, T., Hall, B.M., Gibson, L.F. Blood (2000)
- The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Guzman, M.L., Rossi, R.M., Karnischky, L., Li, X., Peterson, D.R., Howard, D.S., Jordan, C.T. Blood (2005)
- Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Bradstock, K., Matthews, J., Benson, E., Page, F., Bishop, J. Blood (1994)
- Double intensive consolidation chemotherapy in adult acute myeloid leukemia. Harousseau, J.L., Milpied, N., Briere, J., Desablens, B., Leprise, P.Y., Ifrah, N., Gandhour, B., Casassus, P. J. Clin. Oncol. (1991)
- Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53. Yuan, Z.M., Huang, Y., Fan, M.M., Sawyers, C., Kharbanda, S., Kufe, D. J. Biol. Chem. (1996)
- Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. te Boekhorst, P.A., Löwenberg, B., Sonneveld, P. Leukemia (1994)
- Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Stam, R.W., van den Heuvel-Eibrink, M.M., den Boer, M.L., Ebus, M.E., Janka-Schaub, G.E., Allen, J.D., Pieters, R. Leukemia (2004)
- Genetically recessive mutant of human monocytic leukemia U937 resistant to tumor necrosis factor-alpha-induced apoptosis. Dong, J., Naito, M., Mashima, T., Jang, W.H., Tsuruo, T. J. Cell. Physiol. (1998)
- Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry. Lacombe, F., Belloc, F., Dumain, P., Puntous, M., Makhoul, P.C., Saux, M.C., Bernard, P., Boisseau, M.R., Reiffers, J. Blood (1994)
- The contribution of blast cell properties to outcome variation in acute myeloblastic leukemia (AML). McCulloch, E.A., Curtis, J.E., Messner, H.A., Senn, J.S., Germanson, T.P. Blood (1982)
- Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. Amadori, S., Arcese, W., Isacchi, G., Meloni, G., Petti, M.C., Monarca, B., Testi, A.M., Mandelli, F. J. Clin. Oncol. (1991)
- High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia. Lockhart, S., Plunkett, W., Jeha, S., Ramirez, I., Zipf, T., Cork, A., Pinkel, D. J. Clin. Oncol. (1994)